Prabhudas Lilladher has given Accumulate recommendation for Indoco Remedies with a target price of Rs. 480 in its research report issued on Nov 04, 2021

Prabhudas Lilladher’s research report on Indoco Remedies

Indoco Remedies’ (INDR) Q2FY22 performance was muted in regulated market, but should recover with pick up in profit share from Brinzolamide in US and settling of logistics issues in EU markets. The domestic market continued to witnessed strong growth in therapies like anti-infective, GI, VMN and Opthal. We remain structurally positive on INDR on account of 1) MR productivity enhancement and higher penetration in North and East markets 2) new launches in US and 3) higher tender business in EU market. This will continue to sustain current margin trajectory at ~20%.


We recommend ‘Accumulate’ with TP of Rs480 based on 20x Sept 2023E earnings.

Leave a Reply

Your email address will not be published. Required fields are marked *